Loading
Multiple and Secondary Primary Cancers / Ferroptosis and Cancer Prognosis · Journal article
Frontiers in Oncology · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a conceptual State-Transition framework proposing that post-treatment alterations to host genomic, clonal, immune and stromal states may influence second primary cancer risk, integrating inherited susceptibility, aging, and treatment-associated mutagenesis. The framework generates testable hypotheses about the biology of therapy-conditioned hosts but offers no new empirical evidence, clinical trial data, or validation.
Journal article. Cancer survivors at risk for second primary cancers.
Therapy alters somatic selection, clonal architecture, and persistent immune or stromal states in normal tissues Equivalent exposures may generate different host trajectories; distinct treatments may converge on similar biological states Treatment history is an imperfect proxy for biological consequence
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to reorient survivorship research and clinical thinking from treatment exposure alone to the dynamic biological states produced by treatment. Clinicians should view it as a conceptual scaffold requiring prospective validation before clinical implementation.
A conceptual framework proposing mechanisms of second primary cancer evolution based on existing literature; raises testable predictions but presents no new empirical data or clinical evidence.
This framework is intended to reorient survivorship research and clinical thinking from treatment exposure alone to the dynamic biological states produced by treatment. Clinicians should view it as a conceptual scaffold requiring prospective validation before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Second primary cancers (SPCs) are an important challenge in cancer survivorship, yet their heterogeneous biological origins cannot be reduced to treatment exposure. Inherited susceptibility shared environmental and tissue-field effects, ageing, pre-existing somatic mosaicism and treatment-associated mutagenesis contribute to SPC risk. High-resolution studies show that therapy can alter somatic selection, clonal architecture and persistent immune or stromal states in normal tissues. We propose the therapy-conditioned host as a State-Transition framework integrating these observations in survivorship. In this framework, a pre-treatment host state (H 0 ) is perturbed by therapy (P), generating evolving post-treatment states H(t), defined by interacting genomic, clonal, immune and stromal/tissue features. H(t) describes biological state at time t, whereas the sequence H 0 →H(t 1 )→H(t 2 )… defines the host trajectory. Equivalent exposures may generate different trajectories, while distinct treatments may converge on similar biological states. Treatment history is therefore an imperfect proxy for biological consequence. The framework does not imply that all SPCs are therapy-induced, that post-treatment conditioning is inherently carcinogenic, or that clonal expansion is equivalent to malignant progression. It proposes that the magnitude, direction and persistence of treatment-associated changes may influence the evolutionary opportunities of normal and premalignant cells. We outline testable predictions and a translational pathway requiring longitudinal validation, incremental predictive value beyond baseline susceptibility and treatment history, clinical actionability and evidence that intervention improves outcomes without disproportionate harm. The central question is not only what treatment a survivor received, but what biological state it produced, how that state evolves over time, and whether its trajectory meaningfully alters subsequent cancer risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.